Market Overview

UPDATE: Credit Suisse Reiterates Neutral Rating, Raises PT on Aetna

Related AET
KeyBanc: 6 Reasons To Buy Teladoc
The Week Ahead: AMD's Ryzen Anniversary Webinar, CVS Votes On Aetna Merger
CVS Health - Short-Term Pain For Long-Term Gain (Seeking Alpha)

In a report published Friday, Credit Suisse reiterated its Neutral rating on Aetna (NYSE: AET), and raised its price target from $43.00 to $48.00.

Credit Suisse noted, “AET reported 3Q12 operating EPS of $1.55, ahead of our/consensus $1.30/$1.34 and revised 2012 EPS guidance to $5.10, the high end of its previous range of $5.00 to $5.10. The upside was largely driven by lower cost trends and solid operating margins. While the company did not give 2013 guidance, it provided headwinds and tailwinds, and expects EPS to grow next year. We note that the CVH acquisition is expected to be modestly accretive to 2013 EPS and will reinforce AET's capital flexibility.”

Aetna closed on Thursday at $43.95.

Latest Ratings for AET

Jan 2018Credit SuisseMaintainsNeutralNeutral
Jan 2018Deutsche BankUpgradesHoldBuy
Jan 2018PiperJaffrayUpgradesNeutralOverweight

View More Analyst Ratings for AET
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Price Target Analyst Ratings


Related Articles (AET)

View Comments and Join the Discussion!